# MorphoSys (MOR) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/MOR
## Company Profile
- Ticker: MOR
- Exchange: NASDAQ
- Sector: Biotechnology
- Location: United States
- Tags: Biopharma
## Stock Data
- Close: 18.96 USD
- Market cap: Not available USD
- Last updated: 2024-08-02
## Business Overview
MorphoSys is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
## Why The Stock Is Moving

MOR is trading with a steady catalyst profile while investors wait for the next headline that changes the story.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, MorphoSys is followed within the biotech universe for its exposure to catalyst-driven execution.

## Business Model

MorphoSys follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.

## Landscape Position

Compared with more mature healthcare peers, MorphoSys sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.

## Recent News
- 2026-07-21 12:00 EST — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47) — Source: MorphoSys
- 2026-07-20 10:59 EST — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-20 07:00 EST — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 12:00 EST — [Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN](https://biopharmsignal.com/news/MOR/novartis-fabhalta-iptacopan-receives-fda-traditional-approval-as-first-and-only--ec34f769) — Source: MorphoSys
- 2026-07-17 09:00 EST — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc